• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NIMODIPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • NIMODIPINE chembl:CHEMBL1428 Approved

    Alternate Names:

    NYMALIZE
    NIMOTOP
    NIMODIPINE
    BAY-E-9736
    ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
    NIMODIPINUM
    2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-BETA-METHOXYETHYL ESTER 5-ISOPROPYL ESTER
    NIMODIPINO
    2,6-DIMETHYL-4-(3'-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-Β-METHOXYETHYL ESTER 5-ISOPROPYL ESTER
    BAY E 9736
    ISOPROPYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
    NIMOTOP®
    chemidplus:66085-59-4
    rxcui:7426
    drugbank:00393
    pubchem.compound:4497
    chembl:CHEMBL1428

    Drug Info:

    Drug Categories selective calcium channel blockers with mainly vascular effects
    Drug Categories nicotinic acids
    Drug Categories dihydropyridines
    FDA Approval 1988
    Drug Class small molecule
    Drug Indications Vasodilator Agents
    Drug Indications Antihypertensive Agents
    Year of Approval 1988
    Drug Class vasodilator agents
    Drug Class antihypertensive agents
    Drug Groups investigational
    Drug Categories agents causing hyperkalemia
    Drug Categories antiarrhythmic agents
    Drug Categories bradycardia-causing agents
    Drug Categories calcium-regulating hormones and agents
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories moderate risk qtc-prolonging agents
    Drug Categories p-glycoprotein inhibitors
    Drug Categories qtc prolonging agents
    Drug Categories vasodilating agents
    (6 More Sources)

    Publications:

    Kumar et al., 2010, L-type calcium channel blockers, morphine and pain: Newer insights., Indian J Anaesth
    Keyrouz et al., 2007, Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage., Crit Care
    Weant et al., 2010, Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage., Pharmacotherapy
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kim et al., 2009, Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage., J Korean Neurosurg Soc
    Peterson et al., 2006, Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore., Mol. Pharmacol.
    Dong et al., 2010, Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking., Invest. Ophthalmol. Vis. Sci.
    Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol
    Marchetti et al., 1996, High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons., Neurosci. Lett.
    Guntinas-Lichius et al., 1997, Nimodipine maintains in vivo the increase in GFAP and enhances the astroglial ensheathment of surviving motoneurons in the rat following permanent target deprivation., J. Neurocytol.
    Koh et al., 1995, Potentiated necrosis of cultured cortical neurons by neurotrophins., Science
    Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.
    Dietz et al., 2008, A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity., Hypertension
    Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke
    Gahm et al., 2005, Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine., Acta Neurochir (Wien)
    Sinnegger-Brauns et al., 2009, Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms., Mol. Pharmacol.
    Liu et al., Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats., Eur J Drug Metab Pharmacokinet
    Yu DD et al., 2013, Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery., Bioorg Med Chem
    Ko et al., 1993, Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells., J. Hypertens.
  • NIMODIPINE   CACNB4

    Interaction Score: 1.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20661350 17705883 20335610 20334460 19844625


    Sources:
    DrugBank

  • NIMODIPINE   CACNB3

    Interaction Score: 1.35

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20661350 17705883 20335610 20334460 19844625


    Sources:
    DrugBank

  • NIMODIPINE   CACNB1

    Interaction Score: 1.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20661350 17705883 20335610 20334460 19844625


    Sources:
    DrugBank

  • NIMODIPINE   CACNB2

    Interaction Score: 0.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    20661350 17705883 20334460 11752352 19844625


    Sources:
    DrugBank

  • NIMODIPINE   CACNA1F

    Interaction Score: 0.68

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Voltage-gated L-type calcium channel blocker
    Specific Action of the Ligand Antagonist

    PMIDs:
    20661350 20335610 20334460 19844625


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • NIMODIPINE   CACNA1D

    Interaction Score: 0.64

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Voltage-gated L-type calcium channel blocker
    Direct Interaction yes

    PMIDs:
    20661350 17705883 19029287 20335610 20334460 19844625


    Sources:
    DrugBank ChemblInteractions

  • NIMODIPINE   CACNA1S

    Interaction Score: 0.61

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Voltage-gated L-type calcium channel blocker
    Direct Interaction yes
    Direct Interaction? False

    PMIDs:
    20661350 17705883 16675661 20335610 20334460 19844625


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • NIMODIPINE   CACNA1C

    Interaction Score: 0.51

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Voltage-gated L-type calcium channel blocker

    PMIDs:
    20661350 17705883 20335610 20334460 11752352 19205682 19844625 8731425


    Sources:
    PharmGKB DrugBank ChemblInteractions

  • NIMODIPINE   FOS

    Interaction Score: 0.49

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8301097


    Sources:
    NCI

  • NIMODIPINE   NR3C2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Details of Interaction inhibition of aldosterone-induced luciferase activity in a reporter system driven by the mineralocorticoid receptor ligand binding domain
    Endogenous Drug? False

    PMIDs:
    18250364


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • NIMODIPINE   NTF3

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7725105


    Sources:
    NCI

  • NIMODIPINE   CACNG1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    None found


    Sources:
    TEND TdgClinicalTrial

  • NIMODIPINE   GFAP

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9192289


    Sources:
    NCI

  • NIMODIPINE   SERPINE1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11486117


    Sources:
    NCI

  • NIMODIPINE   NOS2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16044358


    Sources:
    NCI

  • NIMODIPINE   CFTR

    Interaction Score: 0.09

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Potentiation

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • NIMODIPINE   NR1H4

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23688559


    Sources:
    DTC

  • NIMODIPINE   AHR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    17327465


    Sources:
    DrugBank

  • NIMODIPINE   CYP3A5

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19205682


    Sources:
    PharmGKB

  • NIMODIPINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14743973


    Sources:
    NCI

  • NIMODIPINE   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB00393

    • Version: 5.1.7

    Alternate Names:
    NIMODIPINE DrugBank Drug Name
    66085-59-4 CAS Number
    Nimodipine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Kumar et al., 2010, L-type calcium channel blockers, morphine and pain: Newer insights., Indian J Anaesth
    Dong et al., 2010, Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking., Invest. Ophthalmol. Vis. Sci.
    Weant et al., 2010, Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage., Pharmacotherapy

  • TEND: NIMODIPINE

    • Version: 01-August-2011

    Alternate Names:
    NIMODIPINE Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Drug Class vasodilator agents
    Year of Approval 1988

    Publications:

  • TdgClinicalTrial: NIMODIPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antihypertensive Agents
    Drug Indications Vasodilator Agents
    Drug Class small molecule

    Publications:

  • DTC: NIMODIPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1428 ChEMBL Drug ID

    Drug Info:

    Publications:
    Yu DD et al., 2013, Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery., Bioorg Med Chem

  • NCI: NIMODIPINE

    • Version: 14-September-2017

    Alternate Names:
    C692 NCI drug code

    Drug Info:

    Publications:
    Koh et al., 1995, Potentiated necrosis of cultured cortical neurons by neurotrophins., Science
    Roos et al., 2001, Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage., Stroke
    Ko et al., 1993, Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells., J. Hypertens.

  • PharmGKB: nimodipine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol

  • GuideToPharmacology: 53801057

    • Version: 29-September-2020

    Alternate Names:
    NIMODIPINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Nimodipine

    • Version: 2020.06.01

    Alternate Names:
    D0XN1F TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1428

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1428

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21